RQM+™ Acquires Germany Based CRO Kottmann
28.8.2023 13:30:00 EEST | Business Wire | Press release
RQM+, a global leader in MedTech services, announces its acquisition of CRO Kottmann, a premier contract research organization (CRO) renowned for its excellent customer service, scientific clinical research and quality in the key market of Germany. This significant move further supports RQM+’s dedication to strategic growth and presence in Europe and emphasizes its dominance in the growing areas of MedTech.
The integration of CRO Kottmann enhances RQM+’s existing geographical footprint in global operations as well as ensures comprehensive end-to-end support for clients, from pre-clinical phases to product commercialization. The addition of CRO Kottmann further expands RQM+'s rapidly growing business as a leading MedTech CRO, driving both existing and new clients’ innovations into pivotal markets.
“We are tremendously excited about this pivotal acquisition. The synergy between RQM+ and CRO Kottmann will propel us to greater heights in the industry. The German market, well known for its emphasis on science, innovation, and market intelligence, is a vital geography for RQM+,” said RQM+ Chief Operating Officer of Clinical Trial Services, David Novotny. “With the combined expertise of both organizations, we will achieve quicker, more efficient operational deliveries that will facilitate a faster market entry for our clients.”
With a reputation for unparalleled customer service and quality, CRO Kottmann brings a wealth of industry-leading knowledge and acumen, positioning RQM+ to leverage these attributes in expanding its global influence, especially in Europe.
“We have always held a like-minded approach to ensuring best-in-class customer service and advisement. This alignment of core values, coupled with our shared ambition to foster growth in science and innovation, will make this partnership a continuation of the success story in Clinical Research. We are pleased to be able to offer our clients an even greater depth of clinical research services. Going forward, our clients can continue using our services to conduct global studies worldwide,” said Tanja Kottmann MD, CEO of CRO Kottmann.
As RQM+ continues its trajectory of growth, the acquisition of CRO Kottmann underscores its commitment to delivering unparalleled service to MedTech manufacturers of all sizes. The acquisition ensures a potent combination of regulatory and clinical experience, industry-leading capabilities, and unrivaled geographical reach, paving the way for swift and innovative solutions in the MedTech space.
DLA Piper served as legal advisor and Translink Corporate Finance as M&A advisor to RQM+.
About RQM+:
RQM+ is the world's leading MedTech service provider offering consulting, clinical trial, lab, and reimbursement services, as well as technology solutions to support the entire product lifecycle. RQM+’s global team of clinical, technical, and top industry experts push the boundaries of excellence. With more former FDA, Medicines, and Healthcare Products Regulatory Agency (MHRA) and notified body regulators than any other firm, the RQM+ team has deep expertise in all clinical specialties. We reduce commercialization risk by offering a full complement of CRO services to progress medical devices, digital therapeutics and diagnostics onto the market and keep them there. In addition to early- and mid-stage MedTech companies, we currently work with 19 of the top 20 medical device manufacturers and seven of the top 10 IVD companies. For more information, visit RQMplus.com.
About Kottmann:
CRO Dr. med. Kottmann, based in Germany, is a leading Contract Research Organization (CRO) celebrated for its unmatched customer service and commitment to quality. As an international CRO, Kottmann conducts clinical studies with medical devices, in vitro diagnostics (IVDs) and pharmaceuticals. In addition to full service, Kottmann also offers individual services such as the creation of databases (eCRFs), statistical evaluations and clinical monitoring for your study. For more information, visit https://www.cro-kottmann.de/en/home_gb.html.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230828710869/en/
Contact information
Media:
Rob Pepper, RQM+
+1.301.254.6100
RPepper@rqmplus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Access Advance Announces New Effective Discount Rates for Its Multi-Codec Bridging Agreement, Starting on January 1, 202711.11.2026 21:18:00 EET | Press release
Access Advance LLC today announced that the Licensors of the HEVC Advance and VVC Advance Patent Pools have independently approved a two-step, phased reduction in the effective royalty discount available under the Multi-Codec Bridging Agreement (MCBA) for Licensees of both pools who sign the MCBA on or after January 1, 2027. Licensees that join both the HEVC Advance and VVC Advance Patent Pools and execute the MCBA on or before December 31, 2026, will secure the current MCBA rates, resulting in an effective discount of up to 50%. Licensees that sign on or after January 1, 2027 will receive a reduced discount as further described below. The MCBA is an administrative agreement, not a separate license, that lets Licensees of both HEVC Advance and VVC Advance Patent Pools pay a single, reduced royalty rate for products that include both HEVC and VVC codecs. Today the MCBA rate for a dual-codec product is the same as the VVC Advance single codec product rate; up to 50% of what a Licensee wo
Angel Aligner Unveils Six Innovations for 202711.11.2026 18:23:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel”), a global clear aligner leader, has unveiled six new clinical innovations, including SuperElastic (MC-SE)* aligner material, a Deepbite Solution for significantly expanded indications, and the Adapt-MATMsystem for next generation growth guidance for young patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110338654/en/ Unveiling Angel's 2027 Innovations. Orthodontists and opinion leaders have long remarked about Angel’s clinical excellence. Orthodontics educator and thought leader Dr. David Sarver said: “In over 4 decades, I’ve never had a parent say I’d be happy if you ensure that my child’s treatment results are average.” Angel is committed to elevating the orthodontic specialty well above the average, especially as more competition and harder referral cases demand outstanding results. Bindu Saran, VP of Product Strategy, added: “Angel was founded by orthodontic profe
Abu Dhabi Future Health Summit Concludes with Research Partnerships and New Programmes to Advance Prevention and Health Innovation11.11.2026 16:58:00 EET | Press release
Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, Abu Dhabi Future Health Summit 2026 concluded with agreements and initiatives spanning drug discovery, clinical research, preventive and reproductive health, alongside research and entrepreneurship programmes that will sustain collaboration beyond the Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111545964/en/ The Summit is the annual flagship gathering of Future Health – A Global Initiative by Abu Dhabi, curated and convened by the Department of Health – Abu Dhabi (DoH) together with Founding Partners PureHealth, M42, Institute for Healthier Living Abu Dhabi (IHLAD) and Mubadala Bio. Held from 20–22 October, the Summit attracted more than 17,300 visitors from 85 countries. It brought together health leaders, researchers, policymakers, investors and inn
De' Longhi Group: Record Results for the Quarter, With Revenue Growing by 7.7% and Net Profit Pertaining to the Group Progressing Significantly by 19%11.11.2026 16:58:00 EET | Press release
The Board of Directors of De' Longhi S.p.A. approved the consolidated results1 for the nine months of 2026. In the nine months the Group achieved: revenues for € 2,621.3 million, up by 6.5% with respect to 2025 (+7.7% at constant currency); an adjusted2 Ebitda of € 455.2 million, equal to 17.4% on revenues (vs. 15.8% with respect to last year); a net income pertaining to the Group equal to € 225.8 million (+20.4% with respect to last year); a positive net financial position equal to € 606.0 million. CEO Fabio de' Longhi commented: “The Group delivered its thirteenth consecutive quarter of organic revenue growth, underscoring our proven ability to capitalize on industry opportunities and respond promptly to market evolution, while ensuring consistent performance across both divisions. The professional business recorded a strong acceleration, spanning all geographies and brands, with revenues growth exceeding 35% for both the quarter and the nine-month period, this against an already par
Starr Chile Assigned A Rating from AM Best11.11.2026 15:30:00 EET | Press release
Starr, a global insurance and investment organization, today announced that the global credit rating agency AM Best has assigned Starr International Seguros Generales S.A. (Starr Chile) a Financial Strength Rating of A (Excellent) and a Long-Term Issuer Credit Rating of a+ (Excellent). The outlook for both credit ratings is positive. The rating reflects Starr’s strong balance sheet and Starr Chile’s successful implementation of Starr’s business model. AM Best also cited Starr’s operating performance, a favorable business profile and enterprise risk management as key factors supporting the positive rating. “This strong rating is another important endorsement of Starr’s business model as we continue to build our presence in Latin America,” said Jeff Greenberg, chairman and co-CEO of Starr. “It reflects the financial strength, underwriting discipline and experienced teams that underpin our business around the world, reinforcing the confidence brokers and clients can place in Starr.” Starr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom